NASDAQ

Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer
Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer
Endpoints
Erytech
NASDAQ
Pferecydes
M&A
Flag link:
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Motley Fool
Moderna Therapeutics
RSV
Bluebird Bio
NASDAQ
Flag link:
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move
Fierce Biotech
Elicio Therapeutics
NASDAQ
cancer vaccines
clinical trials
Angion Biomedica
Flag link:
GE’s board finalizes healthcare spinoff
GE’s board finalizes healthcare spinoff
Medtech Dive
GE Healthcare
Medtech
NASDAQ
Flag link:
Three Biopharma Companies Heading to Nasdaq Through SPACs
Three Biopharma Companies Heading to Nasdaq Through SPACs
BioSpace
SPACs
NASDAQ
Apexigen
Benuvia
Scilex
Flag link:
Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner
Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner
Motley Fool
biotech stocks
NASDAQ
vaccines
Novavax
Moderna Therapeutics
Ocugen
Intra-Cellular Therapies
Caplyta
Flag link:
Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug
Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug
Endpoints
Amylyx
ALS
funding
NASDAQ
Flag link:
Italian cancer gene therapy biotech makes history with modest Nasdaq IPO
Italian cancer gene therapy biotech makes history with modest Nasdaq IPO
Endpoints
gene therapy
IPOs
NASDAQ
Genenta
Italy
Flag link:
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut
Fierce Biotech
Vaxxinity
IPOs
vaccines
immunotherapy
NASDAQ
Flag link:
First Day Trading a Letdown for LianBio in Shadow of Beijing Market Crackdown
First Day Trading a Letdown for LianBio in Shadow of Beijing Market Crackdown
BioSpace
LianBio
Beijing
IPOs
NASDAQ
Flag link:
Two Biopharmas Nix IPO Plans in Unstable Market
Two Biopharmas Nix IPO Plans in Unstable Market
BioSpace
NASDAQ
IPOs
AEON Biopharma
Cingulate
Flag link:
OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO
OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO
Endpoints
IPOs
Theseus Pharmaceuticals
OrbiMed
NASDAQ
Flag link:
Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record
Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record
Endpoints
IPOs
SPACs
NASDAQ
Pasithea Therapeutics
Tyra Biosciences
DiCE Therapeutics
Flag link:
Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger
Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger
Endpoints
Revelation Biosciences
antivirals
SPACs
NASDAQ
Flag link:
BioCryst scraps $200M offering after seeing share price slide
BioCryst scraps $200M offering after seeing share price slide
Fierce Biotech
Biocryst
NASDAQ
funding
Flag link:
Three Biopharma Companies Made Public Debut on Nasdaq Exchange
Three Biopharma Companies Made Public Debut on Nasdaq Exchange
BioSpace
IPOs
Nuvalent
Rallybio
Icosavax
NASDAQ
Flag link:
Amid virtual trial craze, Science 37 earns unicorn status and a trip to Nasdaq on the back of SPAC deal
Amid virtual trial craze, Science 37 earns unicorn status and a trip to Nasdaq on the back of SPAC deal
Endpoints
Science 37
SPAC
NASDAQ
virtual clinical trials
Flag link:
Two Biotechs Gear Up for Nasdaq Debut
Two Biotechs Gear Up for Nasdaq Debut
BioSpace
Gyroscope Therapeutics
Talaris Therapeutics
IPOs
NASDAQ
Flag link:
3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq
3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq
Fierce Biotech
IPOs
NASDAQ
Talaris Therapeutics
Gyroscope Therapeutics
Sagimet Biosciences
Flag link:
It takes two to Tango: The biotech using CRISPR to discover new cancer gene targets rides a $353M SPAC deal to Nasdaq
It takes two to Tango: The biotech using CRISPR to discover new cancer gene targets rides a $353M SPAC deal to Nasdaq
Endpoints
Tango Therapeutics
SPAC
NASDAQ
Flag link:

Pages